Polivy 30 mg, 140 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 14 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with DLBCL.
Dosage (summary)
1.8 mg/kg IV every 21 days for 6 cycles with R-CHP or BR.
Special Populations
- Geriatric use
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; use contraception during treatment and for 9 months after. Discontinue breastfeeding during treatment and for 3 months after.
Key Drug Interactions
- CYP3A inhibitors
- CYP3A inducers
Contraindications
- Hypersensitivity to polatuzumab vedotin
Common side effects
- Peripheral neuropathy
- Nausea
- Neutropenia
- Diarrhea
Counselling Points
- Monitor for infusion-related reactions
- Use effective contraception
- Report signs of infection
Serious warnings
- Serious infections
- Myelosuppression
- Peripheral neuropathy
- PML risk
Important Disclaimer
The Polivy 30 mg, 140 mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
